Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$39.19 USD

39.19
1,019,400

+0.73 (1.90%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.

Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV

by Zacks Equity Research

Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

by Zacks Equity Research

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

Sanghamitra Saha headshot

Grab 5 Top Stocks With Strong Earnings Beat Prospects

by Sanghamitra Saha

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Alnylam's Givlaari Gets Approval in Europe for Rare Disease

by Zacks Equity Research

Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.

GRFS or IONS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. IONS: Which Stock Is the Better Value Option?

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 40.66% and 21.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe

by Zacks Equity Research

Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.

ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study

by Zacks Equity Research

ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

Surging Earnings Estimates Signal Upside for Ionis Pharmaceuticals (IONS) Stock

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

Ionis Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

by Zacks Equity Research

Key highlights of the past week include label expansion of drugs, licensing deals and more.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

by Zacks Equity Research

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

by Zacks Equity Research

Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 96.30% and 16.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?